Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available

Bone Marrow Transplantation volume 50, pages 865–867 (2015)Cite this article

Subjects

An Erratum to this article was published on 03 June 2015

This article has been updated

Allogeneic hematopoietic SCT (Allo-HSCT) using reduced-intensity conditioning (RIC) and non-myeloablative conditioning (NMAC) can be curative for patients with high risk or recurrent hematologic cancers including non-Hodgkin lymphoma (NHL).1, 2, 3 Matched related donors (MRDs) are currently the preferred choice for Allo-HSCT, however, as most patients lack a MRD, the search for an alternative hematopoietic cell source increasingly includes unrelated donors (UDs), unrelated cord blood and eventually haploidentical related donors (HRDs). A newly developed approach for HRD Allo-HSCT using T-cell-replete BM grafts in combination with post-transplantation CY treatment to prevent GVHD and graft rejection has demonstrated promising results, including low rates of non-relapse mortality (NRM) and severe GVHD.4, 5, 6, 7 The aim of this report is to compare HRD with UD and MRD in a retrospective cohort of chemosensitive NHL patients.

All patients selected were in CR or PR at the time of transplantation. Refractory patients (defined as patients who were progressive on therapy or who experienced relapse within 6 months after first line therapy or first relapse therapy) were included if they were chemosensitive.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Change history

  • 03 June 2015

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  1. McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY et al. Allotransplantation for patients age >/=40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant 2014; 20: 960–968.

    Article  Google Scholar 

  2. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 211–217.

    Article  Google Scholar 

  3. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 2010; 16: 78–85.

    Article  Google Scholar 

  4. Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolanos-Meade J et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010; 16: 482–489.

    Article  CAS  Google Scholar 

  5. Luznik L, Jones RJ, Fuchs EJ . High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010; 17: 493–499.

    Article  CAS  Google Scholar 

  6. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  Google Scholar 

  7. O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377–386.

    Article  CAS  Google Scholar 

  8. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  Google Scholar 

  9. Devillier R, Crocchiolo R, Castagna L, Furst S, El CJ, Faucher C et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 2012; 47: 639–645.

    Article  CAS  Google Scholar 

  10. Luznik L, O'Donnell PV, Fuchs EJ . Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 2012; 39: 683–693.

    Article  CAS  Google Scholar 

  11. Patriarca F, Luznik L, Medeot M, Zecca M, Bacigalupo A, Di BP et al. Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol 2014; 93: 187–197.

    Article  CAS  Google Scholar 

  12. Raiola AM, Dominietto A, di GC, Lamparelli T, Gualandi F, Ibatici A et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014; 20: 1573–1579.

    Article  Google Scholar 

  13. Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 2014; 32: 3497–3505.

    Article  CAS  Google Scholar 

  14. Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 2012; 30: 3194–3201.

    Article  CAS  Google Scholar 

  15. Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 2013; 19: 602–606.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Institut Paoli Calmettes, Marseille, France

    S Garciaz, R Bouabdallah, S Fürst, D Coso, J El-Cheikh, F Broussais, C Chabannon & D Blaise

  2. Department of Hematology, Humanitas Cancer Center, Rozzano, Italy

    L Castagna, S Bramanti, R Crocchiolo & A Santoro

Authors
  1. S Garciaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Fürst
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Bramanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Coso
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Crocchiolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J El-Cheikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Broussais
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Garciaz.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garciaz, S., Castagna, L., Bouabdallah, R. et al. Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. Bone Marrow Transplant 50, 865–867 (2015). https://doi.org/10.1038/bmt.2015.22

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.22

This article is cited by

Search

Advanced search

Quick links